Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Should the Lambda (λ) Remain Silent?

Literature DB >> 26660350

Should the Lambda (λ) Remain Silent?

Hossein Haji Ali Afzali¹, Jonathan Karnon², Mark Sculpher³.

Abstract

Mesh：

Year: 2016 PMID： 26660350 DOI： 10.1007/s40273-015-0359-7

Source DB: PubMed Journal: Pharmacoeconomics ISSN： 1170-7690 Impact factor: 4.981

× No keyword cloud information.

30 in total

1. Willingness to pay for a QALY.

Authors: Dorte Gyrd-Hansen
Journal: Health Econ Date: 2003-12 Impact factor: 3.046

2. Real economics needs to reflect real decisions: a response to Johnson.

Authors: Mark Sculpher; Karl Claxton
Journal: Pharmacoeconomics Date: 2012-02-01 Impact factor: 4.981

Review 3. Willingness to pay for a QALY: theoretical and methodological issues.

Authors: Dorte Gyrd-Hansen
Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981

4. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.

Authors: Anthony H Harris; Suzanne R Hill; Geoffrey Chin; Jing Jing Li; Emily Walkom
Journal: Med Decis Making Date: 2008-03-31 Impact factor: 2.583

Review 5. Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence.

Authors: Louise Longworth; Mark J Sculpher; Laura Bojke; Jonathan C Tosh
Journal: Int J Technol Assess Health Care Date: 2011-03-29 Impact factor: 2.188

6. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.

Authors: Mireille M Goetghebeur; Monika Wagner; Hanane Khoury; Randy J Levitt; Lonny J Erickson; Donna Rindress
Journal: Med Decis Making Date: 2011-10-10 Impact factor: 2.583

Should the Lambda (λ) Remain Silent?

1. Willingness to pay for a QALY.

2. Real economics needs to reflect real decisions: a response to Johnson.

Review 3. Willingness to pay for a QALY: theoretical and methodological issues.

4. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.

Review 5. Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence.

6. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.

7. NICE's cost-effectiveness range: should it be lowered?

8. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

9. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence.

10. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?

Review 1. Cost-Effectiveness Thresholds: the Past, the Present and the Future.

2. Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?